Creative Touch Permanent Makeup and Aesthetics

All retinoids produce their effects by delivering all-trans retinoic acid to nuclear RAR receptors, but the path each takes to that endpoint produces meaningfully different clinical profiles. Tretinoin binds all three RAR subtypes and remains the most evidenced single retinoid for photoageing. Adapalene’s selective RARβ/γ affinity spares RARα – the subtype most associated with epidermal irritation – producing equivalent comedolytic and anti-photoageing effects with significantly less irritation. Bakuchiol activates RARα and RARγ through a functionally distinct mechanism, compares to retinol in clinical outcomes with better tolerability, and uniquely upregulates CRABP-II – the intracellular carrier whose decline contributes to age-related retinoid responsiveness loss. The stepping logic from retinol to retinaldehyde to tretinoin is a tolerability sequence, not an evidence sequence.

Retinoids are vitamin A derivatives that share a common biological purpose – activation of retinoic acid receptors (RARs) to drive the gene expression changes described in the Vitamin A entity – but differ substantially in how they reach that endpoint, which receptor subtypes they activate, and what clinical consequences follow from those differences. Understanding the retinoid landscape as a set of mechanistically distinct options rather than a simple potency ladder is what allows clinical selection to be precise rather than default. The RAR/RXR nuclear receptor system that underpins all retinoid activity, including the shared RXRα heterodimerisation with vitamin D receptor signalling, is covered in the Vitamin A entity.

The Retinoid Hierarchy in Clinical Practice

Tretinoin

Tretinoin (all-trans retinoic acid / ATRA) requires no conversion. It binds RARα, RARβ, and RARγ with high affinity and is the most extensively evidenced retinoid in clinical research. A 2022 systematic review of topical tretinoin for photoageing found consistent improvements in wrinkle depth, skin texture, epidermal thickness, and procollagen formation across all studied concentrations (0.025%–0.1%), with histological confirmation of new collagen deposition in the papillary dermis. ^[6] The 6-month timepoint is the minimum for structural collagen changes to become histologically measurable; 12–24 months of consistent use produces progressive improvement. Tretinoin is prescription-only in the UK and most of Europe.

Retinal

Retinaldehyde (retinal) requires one irreversible oxidation step to become ATRA. It is available at cosmeceutical concentrations (typically 0.05–0.1%), has demonstrated both anti-photoageing and antimicrobial effects – the latter relevant for acne-prone presentations – and produces a milder adaptation phase than tretinoin at equivalent ATRA delivery. Its underuse relative to its evidence base is partly a formulation challenge: retinaldehyde is less stable in aqueous formulations than retinol and requires careful packaging to maintain activity.

Retinol

Retinol requires two conversion steps. The majority of topically applied retinol is esterified by the skin before conversion rather than proceeding directly to ATRA, meaning the effective ATRA dose from cosmeceutical retinol concentrations (0.025–0.5%) is substantially lower than equivalent tretinoin concentrations. Clinical evidence supports meaningful improvements at 0.1% and above with consistent use over 12+ weeks; below 0.05%, evidence for structural dermal change is limited. ^[4] Retinol is the best tolerated conventional retinoid and the most widely available without prescription, making it the appropriate starting point for most clients new to retinoids.

Retinyl esters

Retinyl esters (retinyl palmitate, retinyl acetate) are the storage form – they require ester cleavage before conversion to retinol can begin. They are the most stable formulation option and the least irritating, but also the most attenuated in dermal effect. Their primary value is in formulations targeting very sensitive skin where even retinol proves intolerable, or as the vitamin A contribution in traditional emollients such as grass-fed tallow-based preparations.

Adapalene: Third-Generation Selectivity

Adapalene is a synthetic naphthoic acid derivative with selective affinity for RARβ and RARγ. Crucially, it does not significantly bind RARα. ^[3] RARα is the subtype expressed at highest density in basal keratinocytes – and non-selective RARα activation is the mechanism most closely associated with the epidermal irritation, peeling, and erythema that characterise tretinoin’s adaptation phase. Because adapalene bypasses this pathway, it produces comparable comedolytic and anti-differentiation effects in the suprabasal epidermis (mediated by RARγ) and comparable anti-inflammatory effects (mediated by RARβ) with significantly lower irritation. ^[5]

The anti-inflammatory component is worth noting specifically. Adapalene inhibits lipoxygenase activity and arachidonic acid oxidative metabolism – pathways that tretinoin does not suppress directly. For clients where acne inflammation or rosacea-adjacent presentations are a concurrent concern, this additional mechanism is clinically relevant beyond the conventional retinoid benefits.

A 2025 randomised trial found adapalene 0.1% cream produced significant improvements in wrinkle scoring and photoageing scale measurements with good tolerability – confirming that the receptor selectivity that makes adapalene well-tolerated in acne does not come at the cost of anti-photoageing efficacy. ^[8] Adapalene 0.1% gel is currently available OTC in the UK (as Differin), making it the only retinoid with clinical evidence for photoageing available without prescription at meaningful concentrations.

Bakuchiol: Functional Retinoid Mimetic

Bakuchiol is a meroterpene phenol derived from Psoralea corylifolia seeds. It is structurally unrelated to retinoids – it does not share the retinoid molecular backbone – but activates RARα and RARγ through a functionally overlapping mechanism, producing downstream gene expression changes that parallel retinoid activity including COL1A1 upregulation, MMP-1 suppression, and fibroblast proliferation. ^[2]

The 2019 Dhaliwal et al. randomised double-blind trial published in the British Journal of Dermatology – the most cited comparative study – found bakuchiol 0.5% and retinol 0.5% twice daily produced comparable reductions in wrinkle surface area and hyperpigmentation over 12 weeks, with no statistically significant difference between them. Retinol users reported significantly more facial skin scaling and stinging. ^[2] The comparable efficacy finding is real, but the study is comparing bakuchiol to retinol, not to tretinoin, and the 12-week timeframe does not capture the full depth of structural dermal remodelling that longer-term tretinoin produces.

Bakuchiol also has two properties that conventional retinoids do not. First, it increases CRABP-II expression, the intracellular retinoic acid carrier that declines in aged skin and whose loss directly reduces retinoid responsiveness. ^[1] A formulation combining bakuchiol with retinaldehyde produces a 34% increase in CRABP-II, potentially maintaining the delivery machinery that determines how efficiently ATRA reaches the RAR nucleus in aged fibroblasts. Second, bakuchiol has demonstrated enhanced epidermal regeneration in wound healing models, an effect not seen with retinol. These are genuinely novel properties that position bakuchiol as more than simply a tolerable retinol substitute.

What bakuchiol is not is a precise retinoid equivalent. Its receptor activation mechanism is less well characterised than ATRA’s at the molecular level, its evidence base is smaller, and the head-to-head comparison studies are all against retinol rather than tretinoin. For clients who cannot tolerate any conventional retinoid – post-menopausal skin with extreme sensitivity, rosacea-adjacent presentations, reactive barrier states – bakuchiol is a clinically legitimate option with meaningful evidence. For clients who can tolerate retinoids, it is most useful as an enhancer alongside retinaldehyde (for CRABP-II upregulation) rather than a standalone replacement.

The Tolerability Sequence

The stepping logic from retinol to retinaldehyde to tretinoin is a tolerability and availability sequence, not a linear evidence hierarchy. Adapalene sits outside this conventional sequence; its receptor selectivity makes it more tolerable than tretinoin despite being a more potent receptor activator than retinol.

A practical clinical stepping framework:

• Start: Retinol 0.025–0.05%, 2–3 nights per week; build to nightly over 6–8 weeks
• Progress to: Retinol 0.1–0.3% nightly once tolerance is established
• Consider adapalene 0.1% as an alternative step: particularly for oily, acne-prone, or sensitive presentations where RARα-mediated irritation has been the limiting factor with retinol
• Step to retinaldehyde 0.05–0.1% for clients seeking greater efficacy than retinol without prescription-grade adaptation challenges
• Tretinoin 0.025–0.05% (prescription) for established retinoid tolerance, significant photoageing, or where the histologically confirmed collagen deposition evidence is the clinical priority
• Bakuchiol + retinaldehyde for clients with sensitivity profiles that make any conventional retinoid intolerable, or as a maintenance protocol between treatment courses for very reactive skin

Concentration and Evidence Summary

Pregnancy, Breastfeeding, and Topical Retinoid Safety

The teratogenicity concern associated with vitamin A is established for systemic retinoids (isotretinoin, acitretin) and has been confirmed in animal models across the retinoid class. For topical application, systemic absorption is limited but measurable – topical tretinoin at therapeutic doses produces serum levels well below the threshold associated with teratogenic risk in most studies, and no confirmed cases of topical tretinoin-induced teratogenicity have been published. ^[7]

Despite this, the precautionary position for health context is clear: all topical retinoids should be discontinued before conception and throughout pregnancy and breastfeeding. The evidence base for topical retinoid safety in pregnancy is insufficient to recommend continued use, and the benefit-to-risk calculation does not support it when the treatment goal is cosmetic. This is not a legal disclaimer; it is the honest clinical recommendation.